6 results

  • banzel

    (rufinamide)
    Eisai Inc.
    BANZEL is indicated as an adjunctive treatment for seizures associated with Lennox-Gastaut Syndrome in pediatric patients aged 1 year and older, as well as in adults.

  • dayvigo

    (lemborexant)
    Eisai Inc.
    DAYVIGO is indicated for the treatment of adult patients with insomnia, specifically for those experiencing difficulties with sleep onset and/or sleep maintenance.

  • fycompa

    (perampanel)
    Eisai Inc.
    FYCOMPA is indicated for treating partial-onset seizures in patients aged 4 and older, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 12 and older.

  • halaven

    (eribulin mesylate)
    Eisai Inc.
    HALAVEN is indicated for treating metastatic breast cancer in patients who have received at least two prior chemotherapy regimens, including anthracyclines and taxanes, and for unresectable or metastatic liposarcoma in patients previously treated with an anthracycline-containing regimen.

  • lenvima

    (Lenvatinib)
    Eisai Inc.
    LENVIMA is indicated for treating adult patients with radioactive iodine-refractory differentiated thyroid cancer, advanced renal cell carcinoma (in combination with pembrolizumab or everolimus), unresectable hepatocellular carcinoma, and advanced endometrial carcinoma (with pembrolizumab) not amenable to curative surgery or radiation.

  • leqembi

    (lecanemab)
    Eisai Inc.
    LEQEMBI is indicated for treating Alzheimer’s disease in patients with mild cognitive impairment or mild dementia, as established in clinical trials.